Trials / Recruiting
RecruitingNCT06356662
Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease
Efficacy and Safety of Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of tenofovir disoproxil fumarate in the treatment of Parkinson's disease. The changes of motor symptoms and the occurrence of adverse reactions in early Parkinson's disease patients who took tenofovir disoproxil fumarate and did not take Tenofovir disoproxil fumarate at different time points were compared.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tenofovir Disoproxil Fumarate | take tenofovir disoproxil fumarate 300mg/d |
Timeline
- Start date
- 2024-01-23
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2024-04-10
- Last updated
- 2025-02-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06356662. Inclusion in this directory is not an endorsement.